ERBB2 and breast carcinoma: For example, breast carcinomas that are ER-negative, PR-negative, and do not have HER2 over expressed (triple negative) are marked by aggressive behavior, but because women with triple-negative disease are not eligible for tamoxifen or trastuzumab treatment, they usually have relatively low long-term survival [92].